Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar ...

My best advice for anyone recently diagnosed with MBC is to keep a notebook and take someone with you to every appointment.

Metastatic breast cancer treatment with the combination of PCS6422 and capecitabine (NGC-Cap) may increase the cancer-killing ...

Overall, tucatinib add-on to first-line maintenance therapy for HER2-positive metastatic breast cancer delayed progression by ...

Nearly one in 10 adolescent and young adult patients diagnosed with nonmetastatic cancer later develop metastatic recurrence.

The FDA has approved Akeega plus prednisone for adults with deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer.

The current melanoma staging system does not always reflect actual survival outcomes. In some cases, patients with thick but ...

Overall, 71.8% (61.5% confirmed) of patients had partial responses to either of two dose levels of pumitamig plus ...

Title: Results from the randomized Phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma ...

Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease and offered meaningful results in DESTINY-Breast04. In a 2025 real-world ...

For patients living with HER2-positive metastatic breast cancer, the recent FDA approval of trastuzumab deruxtecan (brand ...

Analysts at Jefferies called the approval "highly significant," estimating it could add $2 billion to $3 billion to peak ...